Schering-Plough
SGPSpyGlass Pharma is a late-stage biopharmaceutical company focused on developing long-acting, sustained-release drug delivery systems for chronic eye conditions.
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
SpyGlass Pharma is a late-stage biopharmaceutical company focused on developing long-acting, sustained-release drug delivery systems for chronic eye conditions. The company's core value proposition is transforming the treatment paradigm for glaucoma and ocular hypertension by integrating drug delivery directly into routine cataract surgery, thereby eliminating the need for daily patient adherence to eye drops.
SpyGlass is a clinical-stage innovator attempting to disrupt the glaucoma market by lowering the technical barrier for cataract surgeons to provide interventional glaucoma care without specialized MIGS training.
Questions, answered.
- What is Schering-Plough's market cap?
- Schering-Plough (SGP) has a market capitalization of $671.0M and trades on XNYS.
- Who are Schering-Plough's competitors?
- Schering-Plough's key competitors include Glaukos, Bausch + Lomb, Alcon, and others. These companies compete in similar markets and product categories.
- Who does Schering-Plough partner with?
- Schering-Plough's notable partners include Regents of the University of Colorado.
- Where is Schering-Plough headquartered?
- Schering-Plough is headquartered in United States of America. It has been publicly traded since 2026.